Vanguard Group Inc. Sells 65,227 Shares of Madrigal Pharmaceuticals, Inc. $MDGL

Vanguard Group Inc. cut its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 3.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,812,054 shares of the biopharmaceutical company’s stock after selling 65,227 shares during the period. Vanguard Group Inc. owned about 0.08% of Madrigal Pharmaceuticals worth $831,117,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in MDGL. AlphaQuest LLC increased its stake in Madrigal Pharmaceuticals by 412.5% in the 2nd quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 66 shares during the last quarter. Mather Group LLC. bought a new position in shares of Madrigal Pharmaceuticals in the 3rd quarter valued at about $33,000. Global Retirement Partners LLC grew its holdings in shares of Madrigal Pharmaceuticals by 221.7% in the 3rd quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 51 shares in the last quarter. First Horizon Corp acquired a new stake in shares of Madrigal Pharmaceuticals in the third quarter valued at about $34,000. Finally, GAMMA Investing LLC raised its holdings in Madrigal Pharmaceuticals by 114.3% during the third quarter. GAMMA Investing LLC now owns 90 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 48 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Madrigal Pharmaceuticals News Summary

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Rezdiffra commercial strength: Q4 net sales of roughly $321.1M (Q4) and $958.4M for full‑year 2025, more than 36,250 patients on therapy and nearly $989M in cash and marketable securities — evidence of strong revenue growth and a sizeable cash runway. Press Release
• Neutral Sentiment: Investor materials and transparency: company provided an earnings slide deck and held a conference call — useful for modeling future margins, guidance and pipeline milestones. Earnings Presentation
• Negative Sentiment: Large EPS miss and rising expenses: reported Q4 EPS of ($2.57) vs. consensus ~$0.04, driven by a wider loss as expenses surged despite revenue beating estimates — this prompted an immediate negative market reaction. Zacks Article
• Negative Sentiment: Analyst action: Bank of America cut its price target (from $570 to $529) and set a “neutral” rating, reducing near‑term upside expectations and likely contributing to selling pressure. Benzinga

Insider Activity

In related news, Director Rebecca Taub sold 647 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $492.42, for a total transaction of $318,595.74. Following the completion of the sale, the director directly owned 452,704 shares of the company’s stock, valued at approximately $222,920,503.68. This trade represents a 0.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Paul A. Friedman sold 24,520 shares of the company’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $522.39, for a total value of $12,809,002.80. Following the completion of the transaction, the director directly owned 187,164 shares in the company, valued at approximately $97,772,601.96. This represents a 11.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 99,537 shares of company stock valued at $53,485,702. Company insiders own 21.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on MDGL. Citizens Jmp raised their price target on Madrigal Pharmaceuticals from $527.00 to $745.00 and gave the company a “market outperform” rating in a research note on Tuesday, January 20th. The Goldman Sachs Group restated a “buy” rating and set a $571.00 target price on shares of Madrigal Pharmaceuticals in a report on Wednesday, January 14th. UBS Group set a $900.00 price target on shares of Madrigal Pharmaceuticals in a research note on Friday, December 19th. Wolfe Research set a $579.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Tuesday, January 6th. Finally, B. Riley Financial upped their target price on shares of Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the company a “buy” rating in a report on Thursday, December 11th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $669.86.

Madrigal Pharmaceuticals Price Performance

NASDAQ:MDGL opened at $435.01 on Monday. The company has a market cap of $9.98 billion, a P/E ratio of -33.80, a P/E/G ratio of 20.03 and a beta of -1.01. The firm’s fifty day moving average price is $521.61 and its two-hundred day moving average price is $483.32. Madrigal Pharmaceuticals, Inc. has a one year low of $265.00 and a one year high of $615.00. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.01 and a quick ratio of 3.77.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($2.61). Madrigal Pharmaceuticals had a negative return on equity of 43.76% and a negative net margin of 30.08%.The company had revenue of $321.08 million for the quarter, compared to analyst estimates of $310.36 million. During the same quarter in the prior year, the business posted ($2.71) EPS. The business’s quarterly revenue was up 210.8% compared to the same quarter last year. Equities analysts expect that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current year.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.